AZD1390 Clinical Trials

3 actively recruiting trials across 2 locations

No change since May 2026

Also known as: ATM inhibitor

Pipeline

Phase 1: 2Phase 2/3: 1

Top Sponsors

University of Leeds1
Global Coalition for Adaptive Research1
AstraZeneca1

Indications

Cancer3
Leptomeningeal Disease (LMD)1
Brain Neoplasms, Malignant1
Primary Glioblastoma Multiforme1
Recurrent Glioblastoma Multiforme1

Other1 trial

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

Phase 1

Birmingham, Alabama1 trial

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

University of Alabama at Birmingham

Phase 2/3

Boston, Massachusetts1 trial

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Research Site

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.